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Here we report whole exome sequencing (WES) on a cohort of 71 patients with persistently unresolved white matter abnormalities with a suspected diagnosis of leukodystrophy or genetic leukoencephalopathy. WES analyses were performed on trio, or greater, family groups. Diagnostic pathogenic variants were identified in 35% (25 of 71) of patients. Potentially pathogenic variants were identified in clinically relevant genes in a further 7% (5 of 71) of cases, giving a total yield of clinical diagnoses in 42% of individuals. These findings provide evidence that WES can substantially decrease the number of unresolved white matter cases. ANN NEUROL 2016; 79:1031 -1037 P atients with white matter abnormalities in the central nervous system may have one of more than 100 genetic disorders, including the leukodystrophies (Supplementary Table 1 ). 1 Over the past 2 decades, magnetic resonance imaging (MRI) pattern recognition has transformed the diagnosis of leukodystrophies. 2, 3 Despite these advances, the breadth of conditions that present as a possible leukodystrophy continues to challenge even the most astute clinician. 4 Nearly half of these patients will remain unresolved, resulting in a prolonged diagnostic odyssey for affected families. [5] [6] [7] A number of recent reports have provided evidence that whole exome sequencing (WES) can resolve previously intractable genetic disorders, with diagnostic yields ranging from 16 to 53%. [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] Given the unmet diagnostic need among patients with leukodystrophy, and the potential for agnostic next generation sequencing (NGS) to clarify these cases, we performed WES on a cohort of 71 patients referred to the Myelin Disorders Bioregistry Project (MDBP) for unresolved leukoencephalopathy of presumed genetic etiology. These patients were collected prospectively from August 1, 2009 to July 31, 2013 in the MDBP or the Amsterdam Database of Unclassified Leukoencephalopathies with approval from the institutional review boards at all collaborating institutions, including Children's National Medical Center, the Baylor Neurogenetic Institute, and VU University Medical Center.
Patients and Methods

Cohort Description
A total of 191 persistently unresolved cases were identified during the course of the study. 101 patients were diagnosed using MRI pattern recognition followed by biochemical or other molecular approaches. These testing approaches included lysosomal enzymes, very long chain fatty acids, specific electron transport chain or mitochondrial enzyme assays, urine organic acids, microarray testing of copy number variations, gross chromosomal abnormality testing by karyotype or microarray, plasma amino acids, cerebrospinal neurotransmitters and alpha interferon, urine mucopolysaccharide or sialic acid testing, and targeted molecular testing, for example, for EIF2B1-5, PLP1, or GFAP sequencing based on MRI pattern recognition. Of the 90 persistently unsolved cases, 19 were excluded from WES testing: 9 families obtained access to WES at other facilities, and an additional 10 families were excluded because DNA quality for all members of the trio did not meet minimum quality requirements and attempts to collect additional samples during the course of the study were unsuccessful. Seventy-one families remained for which high-quality samples were available for complete trios. These 30 female and 47 male individuals all had abnormal white matter signal on neuroimaging. Individuals ranged in age from 3 to 26 years at the time of sequencing, but symptom onset ranged from birth to 19 years (see complete Supplementary Case Reports, including a description of the radiologic findings of affected individuals, the phenotypic presentation of affected individuals and their families, and the details of each candidate pathogenic variant identified, available at http://imb.uq.edu.au/download/Vanderver_AON_2016.case_ reports.pdf ). Ethnicities were varied and included individuals of mixed and northern European descent, as well as African American, Arab, African, Asian, and Latin American origin.
WES sequencing was performed at the Queensland Centre for Medical Genomics. Exomes were captured using either the Nextera Rapid Capture kit (Illumina, San Diego, CA) or the SeqCap EZ Human Exome Library v.3.0 (Roche Diagnostics, Risch-Rotkreuz, Switzerland). Captured libraries were sequenced on an Illumina HiSeq 2000 (2 3 100 nucleotides) or on an Illumina NextSeq 500 (2 3 100 nucleotides). WES sequencing was performed such that a minimum of 80% of targeted bases were sequenced to a read depth of 203 or greater (average 5 88%). Reads were aligned to the reference human genome (GRCh37), and pedigree informed variant calling was performed using the Real Time Genomics (Hamilton, New Zealand) integrated analysis tool rtgFamily v3.2. 20 All variants were annotated using SnpEff v3.4 21 and filtered using data from the SnpEff GRCh37.72 database, dbSNP138, and dbNSFP v2.4.
We utilized a custom-built variant annotation and interpretation interface to identify possible causal mutations in each Tables 2-4 ). 22 Cases with variants in known disease genes meeting the American College of Medical Genetics and Genomics (ACMG) criteria for pathogenic or likely pathogenic (see Supplementary Case Reports), and whose clinical features were concordant with the established gene-disease relationship, were classified as diagnostically resolved.
Results
In this cohort, we were able to unambiguously resolve 25 cases (Table 1, Supplementary Table 2 , and Supplementary Case Reports). In 3 cases, we were able to confirm pathogenicity with downstream biochemical testing. For example, Nine of the 25 cases had mutations in genes associated with disorders classically defined as leukodystrophies 3 (see Table 1 and Supplementary Table 1 ); 2 patients were identified with TUBB4A (MIM: 602662)-related hypomyelination (hypomyelination with atrophy of the basal ganglia and cerebellum [MIM: 612438]), 24 Table  1 , Supplementary Table 2 , and Supplementary Case Reports). 30 The remaining individuals had mutations in genes associated with genetic leukoencephalopathies. In these cases, expert review confirmed that the clinical presentation and MRI were consistent with published phenotypes. These findings are consistent with the estimation that a majority of disorders associated with abnormal white matter on neuroimaging are not classic leukodystrophies. 1 This suggests that testing of leukodystrophyassociated genes on NGS panels may have limited diagnostic efficacy (predicted to be only 13% in this cohort), which may outweigh the perceived cost benefit and limiting exposure to incidental findings. In a further 4 cases, we identified 1 or more potentially damaging variants of uncertain significance that did not reach the strict burden of proof required to be classified as pathogenic or likely pathogenic. In each of these cases, the neuroradiological findings, clinical features, and familial segregation of the variants in these individuals were consistent with the published phenotype (Table 2 , Supplementary Table 3 , and Supplementary Case Reports). We therefore classified these variants as potentially pathogenic and considered the cases clinically resolved by expert assessment. This included cases with variants in AMPD2, FLNA, and NDUFA2 (see Supplementary Table 4 ). This also included 1 case (LD_0675) where the individual was reported as part of cohort describing a novel disease due to mutations in AARS2. 27 A final case had a de novo variant in FUS (MIM: 205100) classified as pathogenic by ACMG criteria, but because this gene has previously only been associated with juvenile or adult onset amyotrophic lateral sclerosis (ALS), this was not considered an unambiguous resolution (see Table 2 , Supplementary Table 3 , and Supplementary Case Reports). However, because mutations in other ALS-associated genes are associated with early hypomyelination (including ALS2 [MIM: 205100] in this cohort), and because the de novo finding segregated in this family, it was classified as a potentially pathogenic variant and a clinically resolved case.
To investigate the burden of actionable incidental findings that may be identified during trio-based WES investigation of rare genetic disorders, the Illumina Clinical Services Laboratory screened all 56 adult and 49 pediatric ACMG-recommended genes for potential incidental variants. 31 This analysis revealed pathogenic or likely pathogenic variants in 3 of the 71 families screened ( Table 3 ). The identified variants were restricted to KCNQ1 (MIM: 607542) associated with long QT syndrome and SDHB (MIM: 115310) associated with hereditary paragangliomas (see Table 2 , Supplementary  Table 3 , and Supplementary Case Reports). Interestingly, mutations in SDHB are also now associated with autosomal recessive succinate dehydrogenase deficiency-associated leukoencephalopathy, although the lack of a second mutation in LD_0315 precluded definitive association of this genotype with the patient's phenotype. 32 We found <1 known pathogenic or likely pathogenic variant per 46 adult exomes analyzed, suggesting that the impact of incidental findings is likely to be minimal, especially when weighed against the potential benefits of a successful genetic diagnosis in families with severe, lifethreatening neurologic illnesses (Table 4 ).
Discussion
Using an intention to treat analysis, 33 and if the combined initial cohort of 191 families is considered in which 101 families achieved a diagnosis through standard approaches, the use of the WES approach would result in an 20% diagnostic increase. This yields an overall rate of diagnosis of 73% for the combination of standard and WES approaches. Clinical integration of WES (or whole genome sequencing), therefore, may decrease the number of patients with unsolved genetic white matter disorders from 50% to <30%. Taking into consideration the clinical and psychosocial costs of prolonged diagnostic odysseys in these families, this is substantial. Additionally, although the clinical utility of WES as measured by changes to patient care was not addressed in this study, it should be noted that in several cases the results of WES directly influenced clinical care. For example, patients with ATM and TERT mutations were both referred to specialist clinics where they now undergo oncologic monitoring, and the patient with a de novo KCNT1 mutation was treated with a potassium channel anticonvulsant to control refractory epilepsy. 34 The use of WES in large cohorts enables the identification of sequence variants of varying degrees of clinical certainty. ACMG criteria classify the spectrum of identified variants into 4 tiers; pathogenic, likely pathogenic, variant of unknown significance, or unresolved. 35 However, our study, in which 4 of 30 cases were resolved with MRI pattern recognition 2, 3, 36, 37 and clinical review of the identified variant, suggests that a variant classification system that takes into account clinical context and downstream clinical evaluation and testing (eg, MRI interpretation) should be considered.
In summary, WES has the potential to decrease the number of unsolved cases of leukodystrophy and genetic leukoencephalopathies. Additional research is needed establish the potential value of NGS as a first-line diagnostic tool, and to assess the comparative effectiveness of WES, whole genome sequencing, and targeted panels in this disease population.
